治疗开始前未公开暴露于抗逆转录病毒药物:一项探索性分析。

IF 2.3 4区 医学 Q4 INFECTIOUS DISEASES
Southern African Journal of Hiv Medicine Pub Date : 2021-04-08 eCollection Date: 2021-01-01 DOI:10.4102/sajhivmed.v22i1.1200
Lufuno G Mavhandu-Ramarumo, Lisa A M Tambe, Nontokozo D Matume, David Katerere, Pascal O Bessong
{"title":"治疗开始前未公开暴露于抗逆转录病毒药物:一项探索性分析。","authors":"Lufuno G Mavhandu-Ramarumo,&nbsp;Lisa A M Tambe,&nbsp;Nontokozo D Matume,&nbsp;David Katerere,&nbsp;Pascal O Bessong","doi":"10.4102/sajhivmed.v22i1.1200","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The proportion of individuals with a history of exposure ('pre-exposure') to antiretrovirals (ARVs) prior to formal initiation into antiretroviral treatment (ART) is unknown.</p><p><strong>Objectives: </strong>This study describes the detection of ARVs in plasma and/or hair, of persons who self-reported no pre-exposure to ART at their first-time initiation onto ART in three clinics in the province of Limpopo, South Africa (SA).</p><p><strong>Method: </strong>Concentrations of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) in the plasma and hair of individuals initiating ART were analysed using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Next generation sequences of HIV polymerase gene were analysed with Geneious software 11.15, and drug resistance (DR) mutations were determined according to the Stanford HIV Drug-Resistance database. Participants' demographic data were collected on a structured questionnaire. Data that describe prior exposure to ARV were also collected by this self-reporting method.</p><p><strong>Results: </strong>Paired blood and hair samples were collected from 77 individuals newly initiated onto ART from 2017 to 2019. We detected at least one of the drugs in the plasma or hair of 41/77 (53.2%) patients who responded with a 'no' to the question 'have you received ARVs before initiation onto ART?' Thirty-one participants (<i>n</i> = 31/77, 40.3%) had TDF in either plasma or hair. Emtricitabine and EFV were found in the plasma or hair of 12/77 (15.6%) and 25/77 (32.4%) of participants respectively. Six (<i>n</i> = 6/77, 7.792%) had all three ARVs in plasma or hair. Prevalence of DR mutations at the > 5% significance threshold level in those known to have had ARV-exposure determined by LC-MS/MS prior to ART-initiation was not significant (χ<sup>2</sup> = 0.798; <i>p</i> = 0.372), when compared to those who had no prior exposure but still showed DR.</p><p><strong>Conclusion: </strong>Antiretroviral levels in the hair of individuals initiating treatment imply prolonged prior-exposure to that ARV. The presence of ARV in plasma and hair of persons living with HIV (PLWH) who deny ARV-use, requires an explanation. A larger study at multiple sites and regular DR surveillance of ART-naïve PLWH will be necessary to confirm the generalisability of these findings to the wider South African population.</p>","PeriodicalId":49489,"journal":{"name":"Southern African Journal of Hiv Medicine","volume":" ","pages":"1200"},"PeriodicalIF":2.3000,"publicationDate":"2021-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063556/pdf/","citationCount":"3","resultStr":"{\"title\":\"Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory analysis.\",\"authors\":\"Lufuno G Mavhandu-Ramarumo,&nbsp;Lisa A M Tambe,&nbsp;Nontokozo D Matume,&nbsp;David Katerere,&nbsp;Pascal O Bessong\",\"doi\":\"10.4102/sajhivmed.v22i1.1200\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The proportion of individuals with a history of exposure ('pre-exposure') to antiretrovirals (ARVs) prior to formal initiation into antiretroviral treatment (ART) is unknown.</p><p><strong>Objectives: </strong>This study describes the detection of ARVs in plasma and/or hair, of persons who self-reported no pre-exposure to ART at their first-time initiation onto ART in three clinics in the province of Limpopo, South Africa (SA).</p><p><strong>Method: </strong>Concentrations of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) in the plasma and hair of individuals initiating ART were analysed using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Next generation sequences of HIV polymerase gene were analysed with Geneious software 11.15, and drug resistance (DR) mutations were determined according to the Stanford HIV Drug-Resistance database. Participants' demographic data were collected on a structured questionnaire. Data that describe prior exposure to ARV were also collected by this self-reporting method.</p><p><strong>Results: </strong>Paired blood and hair samples were collected from 77 individuals newly initiated onto ART from 2017 to 2019. We detected at least one of the drugs in the plasma or hair of 41/77 (53.2%) patients who responded with a 'no' to the question 'have you received ARVs before initiation onto ART?' Thirty-one participants (<i>n</i> = 31/77, 40.3%) had TDF in either plasma or hair. Emtricitabine and EFV were found in the plasma or hair of 12/77 (15.6%) and 25/77 (32.4%) of participants respectively. Six (<i>n</i> = 6/77, 7.792%) had all three ARVs in plasma or hair. Prevalence of DR mutations at the > 5% significance threshold level in those known to have had ARV-exposure determined by LC-MS/MS prior to ART-initiation was not significant (χ<sup>2</sup> = 0.798; <i>p</i> = 0.372), when compared to those who had no prior exposure but still showed DR.</p><p><strong>Conclusion: </strong>Antiretroviral levels in the hair of individuals initiating treatment imply prolonged prior-exposure to that ARV. The presence of ARV in plasma and hair of persons living with HIV (PLWH) who deny ARV-use, requires an explanation. A larger study at multiple sites and regular DR surveillance of ART-naïve PLWH will be necessary to confirm the generalisability of these findings to the wider South African population.</p>\",\"PeriodicalId\":49489,\"journal\":{\"name\":\"Southern African Journal of Hiv Medicine\",\"volume\":\" \",\"pages\":\"1200\"},\"PeriodicalIF\":2.3000,\"publicationDate\":\"2021-04-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8063556/pdf/\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Southern African Journal of Hiv Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.4102/sajhivmed.v22i1.1200\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2021/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q4\",\"JCRName\":\"INFECTIOUS DISEASES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Southern African Journal of Hiv Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.4102/sajhivmed.v22i1.1200","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2021/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 3

摘要

背景:在正式开始抗逆转录病毒治疗(ART)之前,有抗逆转录病毒(ARVs)暴露史(“前暴露”)的个体比例尚不清楚。目的:本研究描述了在南非林波波省(SA)的三个诊所中,在首次接受抗逆转录病毒治疗时自我报告没有预先接触过抗逆转录病毒治疗的人的血浆和/或头发中检测到抗逆转录病毒药物。方法:采用经验证的液相色谱-串联质谱(LC-MS/MS)方法,对开始抗逆转录病毒治疗的患者的血浆和头发中替诺福韦(TDF)、恩曲他滨(FTC)和依非韦伦(EFV)的浓度进行分析。利用geneous软件11.15分析HIV聚合酶基因的下一代序列,并根据Stanford HIV drug - resistance数据库确定耐药(DR)突变。参与者的人口统计数据通过结构化问卷收集。通过这种自我报告方法还收集了描述先前接触ARV的数据。结果:从2017年至2019年新开始抗逆转录病毒治疗的77名患者中收集了成对的血液和头发样本。我们在41/77(53.2%)患者的血浆或头发中检测到至少一种药物,这些患者对“在开始抗逆转录病毒治疗之前是否接受过抗逆转录病毒药物”的问题回答为“否”。31名参与者(n = 31/ 77,40.3%)在血浆或头发中发现TDF。血浆或毛发中分别有12/77(15.6%)和25/77(32.4%)检测到恩曲他滨和EFV。6例(n = 6/77, 7.792%)患者血浆或毛发中均有3种抗逆转录病毒药物。在开始抗逆转录病毒治疗前通过LC-MS/MS测定的已知有arv暴露的人群中,DR突变在> 5%显著性阈值水平上的患病率无统计学意义(χ2 = 0.798;p = 0.372),与之前没有接触但仍出现dr的患者相比,结论:开始治疗的个体头发中的抗逆转录病毒水平表明先前接触该抗逆转录病毒的时间较长。否认使用抗逆转录病毒药物的艾滋病毒感染者(PLWH)的血浆和头发中存在抗逆转录病毒药物,这需要一个解释。需要在多个地点进行更大规模的研究,并定期对ART-naïve PLWH进行DR监测,以确认这些发现对更广泛的南非人口的普遍性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Undisclosed exposure to antiretrovirals prior to treatment initiation: An exploratory analysis.

Background: The proportion of individuals with a history of exposure ('pre-exposure') to antiretrovirals (ARVs) prior to formal initiation into antiretroviral treatment (ART) is unknown.

Objectives: This study describes the detection of ARVs in plasma and/or hair, of persons who self-reported no pre-exposure to ART at their first-time initiation onto ART in three clinics in the province of Limpopo, South Africa (SA).

Method: Concentrations of tenofovir (TDF), emtricitabine (FTC) and efavirenz (EFV) in the plasma and hair of individuals initiating ART were analysed using a validated liquid chromatography tandem mass spectrometry (LC-MS/MS) method. Next generation sequences of HIV polymerase gene were analysed with Geneious software 11.15, and drug resistance (DR) mutations were determined according to the Stanford HIV Drug-Resistance database. Participants' demographic data were collected on a structured questionnaire. Data that describe prior exposure to ARV were also collected by this self-reporting method.

Results: Paired blood and hair samples were collected from 77 individuals newly initiated onto ART from 2017 to 2019. We detected at least one of the drugs in the plasma or hair of 41/77 (53.2%) patients who responded with a 'no' to the question 'have you received ARVs before initiation onto ART?' Thirty-one participants (n = 31/77, 40.3%) had TDF in either plasma or hair. Emtricitabine and EFV were found in the plasma or hair of 12/77 (15.6%) and 25/77 (32.4%) of participants respectively. Six (n = 6/77, 7.792%) had all three ARVs in plasma or hair. Prevalence of DR mutations at the > 5% significance threshold level in those known to have had ARV-exposure determined by LC-MS/MS prior to ART-initiation was not significant (χ2 = 0.798; p = 0.372), when compared to those who had no prior exposure but still showed DR.

Conclusion: Antiretroviral levels in the hair of individuals initiating treatment imply prolonged prior-exposure to that ARV. The presence of ARV in plasma and hair of persons living with HIV (PLWH) who deny ARV-use, requires an explanation. A larger study at multiple sites and regular DR surveillance of ART-naïve PLWH will be necessary to confirm the generalisability of these findings to the wider South African population.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.80
自引率
11.80%
发文量
41
审稿时长
>12 weeks
期刊介绍: The Southern African Journal of HIV Medicine is focused on HIV/AIDS treatment, prevention and related topics relevant to clinical and public health practice. The purpose of the journal is to disseminate original research results and to support high-level learning related to HIV Medicine. It publishes original research articles, editorials, case reports/case series, reviews of state-of-the-art clinical practice, and correspondence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信